Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00244907 · ClinicalTrials.gov registry record · Phase 1
Isoflavones for Promoting Calcium Absorption and Preventing Bone Loss in Post Menopausal Women
A Phase 1 study, sponsored by Purdue University.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT00244907: Completed Phase 1 study, sponsored by Purdue University.
NCT00244907 is a Phase 1 study that has completed, run by Purdue University. The registered enrollment target is 23 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (62% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00244907, a Phase 1 study, has completed, sponsored by Purdue University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
Estrogen is a hormone that helps prevent calcium loss and bone breakdown. During menopause, estrogen levels decrease. Insufficient amounts of estrogen may lead to bone loss and possibly osteoporosis. Isoflavones are natural compounds found in soy plants that may help provide protection against bone loss. This study will evaluate the effect of soy isoflavones on calcium absorption and bone loss in post menopausal women.
Interventions
- DIETARY_SUPPLEMENT Genistein vs Risedronate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2006-01 |
| Est. Completion | 2010-05 |
| Phase | Phase 1 |
What the finished NCT00244907 record still lists
NCT00244907 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (62% lower).
The record links to 0 conditions, and to 1 intervention - of which Genistein vs Risedronate is the first listed.
NCT00244907 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00244907 about?
NCT00244907 is a clinical study titled "Isoflavones for Promoting Calcium Absorption and Preventing Bone Loss in Post Menopausal Women". Estrogen is a hormone that helps prevent calcium loss and bone breakdown. During menopause, estrogen levels decrease. Insufficient amounts of estrogen may lead to bone loss and possibly osteoporosis. Isoflavones are natural compounds found in soy plants that may help provide protection against bone ...
What is the current status of trial NCT00244907?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2006-01. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00244907?
The interventions under investigation include: Genistein vs Risedronate (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00244907?
This trial is sponsored by Purdue University, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00244907's enrollment target sits among peer trials
23 1596th of 2000 higher than 400 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia